Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods by English, Emma et al.
1 
 
Performance of the Abbott SARS-CoV-2 IgG II Quantitative antibody assay 1 
including the new Variants of Concern (VOC 202012/V1 (UK) and VOC 202012/V2 2 
(South Africa)): And first steps towards global harmonization of COVID-19 3 
antibody methods 4 
Short title: Quantitative COVID-19 antibody methods 5 
 6 
Authors: Emma English1,2, Laura E Cook2, Isabelle Piec1, Samir Dervisevic1,3, 7 
William D Fraser1,2, W. Garry John1,2 8 
 9 
Affiliations: 1Faculty of Medicine and Health, University of East Anglia, Norfolk, NR4 10 
7TJ, UK, 2Department of Clinical Biochemistry and Immunology, Norfolk and Norwich 11 
University Hospital, Norfolk, NR4 7UY. 12 
3Department of Virology, Norfolk and Norwich University Hospital, Norfolk, NR4 7GJ 13 
 14 
Corresponding Author: 15 
E-Mail: emma.english@uea.ac.uk 16 
Emma English PhD 17 
Faculty of Medicine and Health, 18 
University of East Anglia, 19 
Norwich Research Park 20 
NR4 7TJ 21 









Evaluation Protocol (EP), CLSI, Clinical & Laboratory Standards Institute (CLSI), 29 
Epitope Diagnostics Inc. (EDI), National Institute for Biological Standards and 30 
Control (NIBSC), Limit of Detection (LOD), Limit of Blank (LOB), Limit of Quantitation 31 
(LOQ), quality control (QC), coefficient of variance (CV), Arbitrary Units (AU/mL), 4-32 
parameter logistic (4PL) 33 
 34 
 35 




Background In the initial stages of the SARS-CoV-2 (COVID-19) pandemic a plethora 38 
of new serology tests were developed and introduced to the global market. Many were 39 
not evaluated rigorously and there is a significant lack of concordance in results across 40 
methods. To enable meaningful clinical decisions to be made, robustly evaluated, 41 
quantitative serology methods are needed. These should be harmonized to a primary 42 
reference material, allowing for the comparison of trial data and improved clinical 43 
decision making.  44 
Methods A comprehensive evaluation of the new Abbott IgG II anti-SARS-CoV-2 IgG 45 
method was undertaken using CLSI based protocols. Two different candidate primary 46 
reference materials and verification panels were assessed with a goal to moving 47 
towards harmonization.  48 
Results The Abbott IgG II method performs well across a wide range of parameters 49 
with excellent imprecision (<3.5%) and is linear throughout the positive range (tested 50 
to 38,365 AU/mL). The sensitivity (based on ≥14 day post positive RT-PCR samples) 51 
and specificity are 98.3% [90.6-100.0%] and 99.5% [97.1-100%] respectively. The 52 
candidate reference materials showed poor correlation across methods with mixed 53 
responses noted in methods that use the spike protein versus the nucleocapsid 54 
proteins as their binding antigen.  55 
Conclusions The Abbott IgG II anti-SARS-CoV-2 measurement appears to be the 56 
first linear method potentially capable of monitoring the immune response to natural 57 
infection, including from new emerging variants. The candidate reference materials 58 
assessed do not generate uniform results across several methods and further steps 59 





SARS-CoV-2 has swept the globe at an alarming rate with a reported 90 million cases 63 
and 1.9 million deaths by the one year anniversary of the first death of this pandemic 64 
(1) and increasing to 119 million cumulative cases and over 2,6 million deaths by the 65 
middle of March 2021 (2). In this time there has been an unprecedented global effort 66 
to identify new diagnostic tests, treatments and more recently vaccines against the 67 
virus and the associated disease, COVID-19. 68 
The development and delivery of a range of vaccines against the virus is underway, 69 
with several already approved for use and others in late stage clinical trials (3). 70 
Although there are several different approaches to the design of these vaccines a 71 
common factor is the use of the spike proteins, in the form of the attenuated whole 72 
virus, or portions of the spike protein such as the receptor binding domain or through 73 
the use of nucleic acids directed to the synthesis of the spike protein.  74 
In the United Kingdom a national immunization programme has been launched, with 75 
a tiered system of invitations to receive the vaccine dependent on risk of a negative 76 
outcome from the disease (4). Whilst there is trial data for each of the vaccines in use, 77 
there is limited data regarding the quantitative changes in antibody concentrations 78 
over time following vaccination. With the introduction of a national immunization 79 
programme it will be important to understand the antibody response to immunization 80 
in terms of; development, peak concentration and decline over time to assess efficacy 81 
of the vaccination delivery. In order to do this, two elements are required; a robust 82 
quantitative SARS-CoV-2 IgG method, which is directed against the spike protein and 83 
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a commutable standard or reference material to allow comparison of results across 84 
different methods and thus different trials or immunization programs (5).  85 
This study evaluates several assay performance criteria (such as precision and 86 
sensitivity) using recognized and standardized evaluation protocols (EP), for the new 87 
Abbott SARS-CoV-2 IgG II Quant method on the Alinity i system (Abbott Diagnostics, 88 
Chicago, US) and explores the different materials available that may form the basis of 89 
a candidate international reference standard for harmonization programs (6).  90 
 91 
Methods 92 
Sample collection and storage All procedures were performed in accordance with 93 
the ethical standards of University of East Anglia for de-identified samples for method 94 
development and in concordance with the Helsinki Declaration. Serum samples were 95 
collected, anonymized, aliquoted and stored at –80oC until analysed. SARS-CoV-2 96 
Positive samples (P) were from patients with PCR confirmed infection (AusDiagnostics 97 
platform, Chesham, UK, The Panther, Manchester, UK and The Altona Hamburg, 98 
Germany). All RT-PCR assays have dual genome target. Key performance testing 99 
including precision, limit of quantitation (LoQ), linearity, and method comparison were 100 
assessed per Clinical and Laboratory Standards Institute (CLSI) protocols which 101 
ensured standardized testing procedures were used. 102 
 103 
Summary of Abbott assay The SARS-CoV-2 IgG II Quant assay is an automated 104 
two-step, chemiluminescent microparticle immunoassay (CMIA). It is used for the 105 
qualitative and quantitative determination of IgG antibodies to the receptor binding 106 
domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2, in human serum 107 
6 
 
and plasma on the Alinity i system. The sequence used for the RBD was taken from 108 
the WH-Human 1 coronavirus, GenBank accession number MN908947. The analytical 109 
measurement interval is stated as 21-40,000 AU/mL and positivity cut-off is ≥50 110 
AU/mL (manufacturer defined). 111 
 112 
CLSI EP-5 and EP-15 imprecision Both CLSI EP-5 and EP-15 based protocols were 113 
used to evaluate the imprecision of the assay. For the EP-15 study, three different QC 114 
levels (Abbott Diagnostics) were used (one negative and two positive) and five 115 
replicates were measured twice a day for five days. For the EP-5 study, four patient 116 
serum pools (one negative and 3 different positive) were measured in duplicate, twice 117 
a day for 20 days.  118 
 119 
CLSI EP-6 linearity Dilutions of a high patient sample (mean value 38,365 AU/mL, 120 
from triplicate measurement) were made using the Abbott diluent to generate a series 121 
of samples with antibody concentrations over 95% of the analytical measurement 122 
range of the assay. All samples were measured in triplicate.  123 
 124 
Limit of Quantitation (LOQ) and Limit of Detection (LOD) The LOQ was 125 
determined by measuring five negative patient pools in quintuplicate, twice a day for 126 
two days. The LOQ was estimated as the lowest concentration with a 20% CV (7). As 127 
defined in CLSI EP17, LOD is determined by utilising both the measured limit of the 128 
blank (LOB) and test replicates of a sample known to contain a low concentration of 129 
analyte using the equation LoD = LoB + 1.645(SD low concentration sample) (7) The Abbott 130 




Cross reactivity samples Negative control samples were from healthy patients with 133 
no recorded history of infection or immune disorders and collected in 2018, prior to the 134 
emergence of COVID-19. Pre-pandemic samples from patients who had a range of 135 
confirmed respiratory infections (including Influenza A, B and seasonal coronaviruses 136 
were included in the cross-reactivity analysis). Samples from patients positive for 137 
thyroid stimulating immunoglobulin (TSI) were analysed to test the non-specific 138 
binding of non-SARS-CoV-2 antibodies in the assay. These groups of samples are 139 
referred to as N (negative control), CR (cross-reactivity), TSI (patients with thyroid 140 
stimulating immunoglobulin); for further details on samples and collection please see 141 
reference (8). A total of 334 individual serum samples (143 P, 65 N, 97 CR and 29 142 
TSI) were analysed for SARS-CoV-2 IgG antibodies.  143 
 144 
Specificity and sensitivity analysis The quantitative IgG levels were measured at 145 
different time points after a confirmatory RT-PCR test for SARS-CoV-2 allowing for 146 
analysis at pre and post 14 days from RT-PCR date, along with the cross reactivity 147 
samples these were used to determine sensitivity and specificity.  148 
A concordance analysis was undertaken comparing the Abbott quantitative method 149 
with 3 other SARS-CoV-2 IgG immunoassay methods: 1) Epitope Diagnostics Inc. 150 
(EDI, San Diego, CA, USA) performed using the Agility ELISA automate (Dynex 151 
Technologies, Chantilly, VA, USA), 2) Abbott Diagnostics (qualitative method) 152 
(Maidenhead, UK) on the Alinity™ i analyser and 3) DiaSorin (Dartford, UK) on the 153 




New variant samples As the pandemic progresses new variants of the virus emerge 156 
raising concern that the mutations in these variants may render immunoassays 157 
ineffective, as the antigenic changes that arise may no longer represent the antigenic 158 
regions of the reagents in the assay. The main SARS CoV-2 lineage circulating in the 159 
autumn of 2020 in the UK was B.1.177 (the Spanish lineage). However, since January 160 
2021 the ‘UK variant’ (VOC 202012/01 or B1.1.7) has become the predominant virus 161 
in the UK (9). Furthermore, by the beginning of March 2021 there have been in total 162 
266 confirmed and probable cases of ‘South Africa’ variant (VOC 202012/02 (B.1.351). 163 
These new variants have several mutations in different parts of SARS CoV-2 genome 164 
with some within the Receptor Binding Domain increasing the virus transmissibility. 165 
The RBD of the ‘UK’ (VOC 202012/01 or B1.1.7) strain, which is the predominant virus 166 
in the UK, contains mutation N501Y in the RBD domain of the Spike protein amongst 167 
15 other mutations in the other genome areas. This variant has since January 2021 168 
acquired another RBD mutation, E484K, in addition to the variant defining mutations 169 
which resulted in designation as VOC 202102/02 (B1.1.7 cluster with E484K). E484K 170 
is currently the mutation with most evidence of causing antigenic change (10). The 171 
RBD of ‘South Africa’ (VOC 202012/02 or B.1.351) variant contains RBD K417N 172 
mutation in subsets of isolates in addition to the E484K and N501Y RBD mutations.  173 
Viruses containing the above mutations are not very similar to the predominant virus 174 
(B.1.177 ) in circulation in the summer and autumn of 2020.  175 
We analysed samples from patients proven to have the VOC 202012/v-1 (UK) strain 176 
which is now a predominant virus in the UK, as well as one imported cases of the VOC 177 




CLSI EP-9 (trueness) Although a small number of assays are marketed as 180 
quantitative methods there are no standardized reporting units making method 181 
comparisons difficult. It was considered inappropriate to evaluate trueness using a 182 
standard CLSI EP-9 protocol. See section below for further discussion. 183 
 184 
Identifying potential standards and reference materials – In order to progress the 185 
harmonization of SARS-CoV-2 Ig immunoassay methods, a certified reference 186 
material (CRM) is needed. Several candidate standard materials were evaluated on 187 
each of the four methods described above. Three different materials were obtained 188 
from the National Institute for Biological Standards and Control (NIBSC) and assayed. 189 
These consisted of:  190 
• A CE marked verification panel of 37 samples (NIBSC code 20/B770). Each 191 
sample consisted of 0.3 mL of human plasma containing the bacteria growth 192 
inhibitor Bronidox® at 0.05% (w/v). Twenty-three samples were convalescent 193 
plasma packs known to be anti-SARS-CoV-2 positive and the remaining 14 194 
were detailed as negative.  195 
• A CE marked ‘working standard’ (NIBSC code: 20/162) intended for use as a 196 
Diagnostic Calibrant to monitor the sensitivity of assays. The standard 197 
consisted of convalescent plasma positive for anti-SARS-CoV-2 antibodies 198 
pooled from three different donors. Frozen liquid (0.3 mL) was supplied. ‘The 199 
material has been assigned an arbitrary unitage of 1000U.’ A series of dilutions 200 
were made to assess the linearity at the positive cut off value. 201 
• A CE marked ‘Quality Control 1’ (NIBSC code: 20/B764) intended for internal 202 
quality control use for immunoassays that detect SARS-CoV-2 antibodies. The 203 
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material was supplied as a ready to use reagent of plasma positive for anti-204 
SARS-CoV-2 antibodies, derived from two different donors and diluted in 205 
defibrinated convalescent plasma, preserved with Bronidox® at 0.05% (w/v). 206 
A panel of heat inactivated ‘reference materials’ with 5 positive samples and 1 negative 207 
sample from Technopath, were assayed (Technopath, Tipperary, Ireland). The 208 
manufacturer information suggests the samples are a series of pre-diluted samples 209 
from a positive stock. The primary material, the diluent used, and the heat inactivation 210 
process were not described.  211 
 212 
Statistics Calculations were performed using SPSS Statistics (IBM) 25.0.0.1.  or 213 
GraphPad Prism version 8.0 (GraphPad Software, Inc., USA). Cohen’s Kappa tests 214 
was used to determine the concordance between the assays. Analysis of CLSI EP-15 215 
was performed using the software EP evaluator (Data Innovations, Build 11.3.0.23). 216 
Throughout the tables, figures, and legends, the following terminology is used to show 217 
statistical significance: *P<0.05; **P<0.01 and ***P<0.001. 218 
 219 
Results 220 
CLSI EP-5 and EP-15 imprecision Supplemental Table 1 shows the performance of 221 
a negative and two positive QC samples using the CLSI EP-15 based protocol. The 222 
mean value of the negative sample was very low (3.4 AU/mL) and outside of the 223 
analytical measurement range, hence the high CV at that level, however the SD value 224 
is low (SD 0.7) inferring good performance. The imprecision of the positive QC material 225 
was low (3.0% and 3.3% total CV). 226 
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The imprecision data based on CLSI EP-5 is presented in Table 1. Again, this shows 227 
a high CV in the negative samples (mean 2.7 AU/mL, SD 1.74) but the more relevant 228 
total CV in the each of the three positive samples remains below 3.5% CV. 229 
 230 
CLSI EP-6 linearity CLSI states for EP-6 that goals for linearity should be derived 231 
from goals for bias and should be less than or equal to these goals. Figure 1 shows 232 
the linearity of a diluted sample over the working range of the assay, it is linear up to 233 
38,365 AU/mL as tested (manufacturer claim is 40,000 AU/mL). This was the highest 234 
patient sample value available measured neat that was under 40,000 AU/mL and was 235 
acceptable as this high sample was within 5% of the upper limit. Supplemental Table 236 
2 details the % difference from the target values for each dilution. Linear fitting was 237 
performed and showed a slope of 1.004 (95%CI 0.9923-1.017) with a r2=0.9992. The 238 
model was tested and returned a p P<0.001, indicating non deviation from the linearity.   239 
 240 
Limit of Quantitation (LOQ) and Limit of Detection (LOD) The means and the CVs 241 
(%) of the samples for the LOQ were 3.8 AU/mL (59.3%), 18.1 AU/mL (13.6%), 30.4 242 
AU/mL (5.4%), 36.9 AU/mL (3.4%) and 52.2 AU/mL (3.9%). The LOQ was estimated 243 
as the lowest concentration with a 20% CV. Using a 4-PL curve-fit; the LOQ was 244 
calculated at 15.4 AU/mL. As defined in CLSI EP17, LOD is determined by utilising 245 
both the measured LOB (0.1 AU/mL) (lower limit of blank) and test replicates of a 246 
sample known to contain a low concentration of analyte. The LOD was determined as 247 




Cross reactivity samples Patient samples (n=97) from people with respiratory 250 
infections, collected in 2018 and 2019 prior to the COVID-19 pandemic were analysed. 251 
The results ranged from 1.1 AU/mL to 48.3 AU/mL, with a mean value of 6.9 AU/mL. 252 
All but one samples were reported as negative, but one was also close to the cut-off 253 
of 50 AU/mL (manufacturer defined). One sample had a value of 140.5 AU/mL but was 254 
negative on the qualitative IgG assay and the IgM assay. In addition to these CR, 29 255 
TSI samples were also analysed and all returned negative values from 0.0-29.0 256 
AU/mL. Data is summarised in Table 2. 257 
 258 
Specificity and sensitivity Table 2 details the sensitivity and specificity of the method 259 
with analysis of SARS-CoV-2 RT-PCR positive samples at all time points and at >14 260 
days post confirmatory test. The data shows that the method has a sensitivity of 91.6% 261 
in all time points and 98.3% at >14days, and a specificity of 99.4%.  262 
The analysis of assay concordance revealed a mixed pattern of agreement with the 263 
highest between the Abbott quantitative method (IgG II) and the Abbott qualitative 264 
method with a Cohen’s Kappa of 0.965 and agreement of 98.4% and the poorest 265 
between the DiaSorin and other methods (Cohen’s Kappa of 0.930, agreement of 266 
96.7% between the Abbott quantitative and the DiaSorin methods, see figure 2. 267 
 268 
New variant samples The results clearly show that the Abbott IgG II method detects 269 
the original strain of SARS-CoV-2 as well as two new Variants of Concern, the VOC 270 
202012/v-1 (UK) strain and the VOC 202012/v-2 (South Africa) strain. Figure 3 shows 271 
a time course for a subset of 4 different patients charting the increase in antibody 272 




Identifying potential standards The analysis of the 37 samples from the NIBSC 275 
‘verification panel’ produced the expected classification of 23 positive and 14 negative 276 
samples, with a clear separation between the two groups on the Abbott IgG II assay, 277 
see Supplemental Table 3. The range of the positive values was 210 – 9710 AU/mL. 278 
The values for the negative samples of 0.7-5.6 AU/mL, were significantly below the 279 
≥50 AU/mL threshold for classification as a positive sample. As expected, these values 280 
are markedly different to the values presented for other methods. In order to allow 281 
comparison of the results between the different methods and to standardize the 282 
results, the individual values were normalized to the highest responding sample for 283 
each method which was set to a normalizing value of 1. Thus, the results of the positive 284 
samples for each method were divided by the highest value obtained by that method 285 
for any of the positive 23 samples. So, if the highest positive values were 50 and 23 286 
for two methods, all positive samples were divided by 50 for the first method and by 287 
23 for the second method. This provided all values as a ratio of the highest value 288 
obtained for any sample on an individual method. This should demonstrate if the 289 
magnitude of positive response compares between methods, see Supplemental 290 
Figure 1. Figure 1 shows that methods which use spike proteins as the assay antigen 291 
produced similar results. Methods that used the nucleocapsid antigen are similar. 292 
However, there is a lack of agreement between these two method types (spike Ag 293 
versus nucleocapsid Ag).   294 
The analysis of the NIBSC ‘working standard’ (NIBSC code: 20/162) and Quality 295 
Control 1 (NIBSC code: 20/B764) samples generated mean values of 14,072 AU/mL 296 
and 296.6 AU/mL respectively on the Abbott IgG II method, as a mean of triplicates. 297 
This is significantly different to the arbitrary ‘1000 U’ assigned to the working standard. 298 
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It should be noted that no volume is detailed in the unit assignment. The dilution of the 299 
NIBSC 20/162 working standard proved linear. The slope was 0.9981 (95%CI 0.9836-300 
1.013) with a r2=0.9997. Model test showed no deviation from the linear model with 301 
p=0.2500). The % difference from expected is detailed in Supplemental Table 4, the 302 
range was 4.6-9.7% difference to a value of 20 AU/mL on dilution.  303 
The Technopath series proved to be linear when measured on the quantitative 304 
method, this was expected as the samples represent a dilution series. Although the 305 
diluent is not described it does not appear to have had an impact on the linearity of 306 
the dilution series. The range of values obtained were 5.6 AU/mL for the negative and 307 
147.5 – 4,098 AU/mL for the positive samples. Figure 4 shows comparison graphs of 308 
the values obtained with the Abbott IgG II versus different methods (DiaSorin Liaison 309 
XL, EDI, Abbott IgG (qual)). The other methods are clearly calibrated towards the 310 
negative/positive threshold and are not linear using this material.  311 
 312 
Discussion 313 
Quantitative SARS-CoV-2 IgG II method evaluation The focus of many method 314 
evaluations to date has been on the diagnostic accuracy of the assay; does it correctly 315 
identify those with or without antibodies to the SARS-CoV-2 virus? However many 316 
publications have neglected to fully address the analytical performance of these 317 
methods, which ultimately has a significant impact of the potential clinical utility of 318 
these tests. There are over 300 different methods in development or available for 319 
purchase that aim to detect SARS-CoV-2 IgG and whilst some have undergone a 320 
robust evaluation, many on the market have not (11, 12). This is the first evaluation of 321 
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the pre-launch Abbott anti- SARS-CoV-2 IgG assay (IgG II) on the Alinity i system and 322 
the data clearly show that it meets many of the expected performance criteria. 323 
The method achieved an excellent precision profile which is well within the ≤ 15% CV 324 
often cited as the minimum criteria set by the Food and Drugs Administration (FDA) 325 
and the European Medicines Agency (EMA) (13). The method is linear across a wide 326 
working range. The sensitivity and specificity are very high at 98.3% [90.6-100%] for 327 
samples ≥ 14 days post positive RT-PCR, 91.6% [85.8-95.6%] for all samples and 328 
99.5% [97.1-100%] respectively. Although concordance with other methods varied, it 329 
is important to note that this is the first quantitative assay for SARS-CoV-2 IgG and 330 
therefore difficult to make direct comparisons, the poorest concordance was with the 331 
DiaSorin method, reflecting previously published data (14-16).  332 
It is reassuring to see that the method also identifies antibodies in patients with the 333 
two new Variants of Concern (VOC 202012/v-1 (UK) VOC 202012/v-2 (South Africa) 334 
strain), and that an increase in antibody levels occurs as the immune response 335 
evolves. It is important that any method used to monitor immune response to infection 336 
is able to detect antibodies that arise from a variety of emergent variants, otherwise 337 
false negative diagnoses may arise.  338 
 339 
Identification of candidate primary reference material A robust approach to 340 
harmonization of serology methods is essential in order to understand the ongoing 341 
impact of both natural infection and vaccination on the immunity of the population to 342 
SARS-CoV-2. This study and our previous data (15) have shown a significant  disparity 343 
in the performance of different commercial methods in terms of linearity (Figure 4), 344 
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units of measurement (Figure 4) and even sensitivity and specificity (Figure 2, Table 345 
2 and reference (15)).  346 
This study evaluated candidate reference materials for the harmonization of anti-347 
SARS-CoV-2 antibody methods. Much hope has been placed on the rapid introduction 348 
of vaccines against this virus but many questions on their efficacy remain unanswered. 349 
Questions such as; are two doses of the vaccine needed? What time interval is most 350 
effective? What is the magnitude and duration of the immune response? What level of 351 
antibodies in circulation are needed to continue to afford protection? All these 352 
questions require multiple, large scale and multi-site studies to answer, which in return 353 
need robust and consistent serology measurements. Studies in children who have 354 
been vaccinated for Rubella virus show that approximately 9% are seronegative after 355 
the first dose decreasing to <1% after the second, clearly indicating the value of the 356 
second dose (17, 18). Antibody levels present in a population are higher when due to 357 
naturally occurring immunity or post vaccination boosts from virus exposure than 358 
levels that arise through immunization alone, meaning the expected values for Rubella 359 
antibodies have decreased as immunization programmes have widened their reach 360 
(18), this may be mirrored over time with the SARS-CoV-2 antibody levels in the 361 
general population meaning any derived target values for positive serology and the 362 
limits of quantitation of methods will need to adapt over time.  363 
In order to achieve the goal of harmonized serology testing for anti-SARS-CoV-2 364 
antibody methods the principles of metrology must be applied (19-21). Key 365 
components of a system of traceability include a defined measurand, a primary 366 
reference material (preferably approved by a certifying authority such as IFCC, ISO, 367 
ICM, NIST etc), a higher order measurement system or reference method procedure 368 
and a known calibration hierarchy. Metrological traceability is the property of a 369 
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measurement result whereby the result can be related to a reference through a 370 
documented unbroken chain of calibrations, each contributing to the measurement 371 
uncertainty (20). Whilst this has been achieved for analytes such as HbA1c there has 372 
been less success with serology testing for viruses such as Rubella and to date very 373 
limited attempts for anti-SARS-CoV-2 antibody methods (18, 22, 23).  374 
Hurdles to overcome include the availability of a reference measurement procedure 375 
and a primary reference material. The immune response to an antigen challenge is 376 
heterogenous and therefore defining the measurand is difficult. Three components 377 
comprising the system (or matrix such as plasma), the component (the anti-SARS 378 
CoV-2 IgG) and a measurement quantity such as the biological response or biological 379 
activity, together form the measurand of interest. It is expected that a primary 380 
reference material for such complex analytes will undergo state of the art purification 381 
steps with identification of class and subclass of immunoglobulin and some type of 382 
functional assessment of biological activity. International Units per millilitre (IU/mL) 383 
should be used and the reference material should be commutable across methods (6, 384 
24). Once a primary reference material has been defined all future reference materials 385 
should refer to this material rather than the previous batch.  386 
This standardization process has proven difficult for serology methods, with Rubella 387 
virus IgG methods an example of how poor agreement is between some methods (25). 388 
This has the potential to lead to misinterpretation of results, sometimes causing 389 
adverse clinical outcome. Factors which influenced the lack of standardization include: 390 
the use of an immunoglobulin preparation from human serum, with limited purification 391 
steps, which are not described. The effect on biological activity of the preparation, 392 
lyophilization and subsequent reconstitution was not assessed. Guidance on 393 
appropriate diluents was not provided. Similarly, these are the same conditions under 394 
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which the current available references materials for SARS-CoV-2 antibody methods 395 
are prepared and the same questions around performance are being raised.  396 
Our data shows that the current anti-SARS-CoV-2 antibody methods do not compare 397 
well in terms of units of measurement, linearity, magnitude of response and relative 398 
response in different patient samples. Those methods which detect antibodies directed 399 
against the spike protein appear to have greater concordance with each other than 400 
those that detect the nucleocapsid. Some of this may be due to the calibration of the 401 
methods, with only the Abbott IgG II quantitative method being linear so far. The 402 
materials currently available as candidate primary reference material show 403 
considerable variation across methods and the preparation and performance of these 404 
materials is poorly described. Without steps to improve the quality of these reference 405 
materials, including a description of the antibody populations within the reference 406 
material (i.e. predominantly nucleocapsid or spike protein recognition), the scientific 407 
community is likely to encounter similar pitfalls to those that previous attempts to 408 
harmonize serology methods have experienced. 409 
Conclusions It is clear to see that there is a long road ahead to achieve harmonization 410 
of anti-SARS-CoV-2 antibody methods and urgent action is needed to ensure that 411 
manufacturers and regulatory bodies work synergistically towards the goal of 412 
harmonization. 413 
The Abbott IgG II method performed well in this evaluation and is the only method 414 
tested that shows linearity over a wide concentration range and potential external 415 
calibration materials. It is suitable for future studies investigating the clinical response 416 
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Table 1: EP-5 (20 day imprecision data) generated using pool patient material at 425 
four levels, one negative and three positives.  426 
  
Negative 
patient pool  
Positive patient 
pool 1  
Positive patient 












  %CV SD %CV SD %CV SD %CV SD 
 
Total   
64 1.74 2.9 2.09 3.3 9.3 3.4 83.4 
  427 
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Table 2: Summary table of the sensitivity, specificity and cross-reactivity samples of 428 
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 494 
Figure Legends: 495 
Figure 1: Linearity of method over the complete working range of the Abbott IgG II 496 
assay using a range of dilutions of a high positive (mean 38,365 AU/mL) in the 497 
Abbott diluent. Dash-dot grey line indicates the identity line. The black dotted line 498 
represents the 95% likelihood asymmetrical CI of the slope.  499 
Figure 2: Cohen’s Kappa concordance analysis of the assays and overall (all 500 
samples included) agreement of results given as %. Equivocal results were 501 
considered negative 502 
Figure 3: Representative examples of the quantitative immune response in three 503 
different variants of the SARS-CoV-2 virus, including the ‘UK’ and ‘South Africa’ 504 
variants. The days post-PCR do not necessarily correlate to the day of onset of 505 
symptoms or the day of hospitalization. 506 
Figure 4: Comparison graphs of the values obtained for the Technopath positive 507 
panel with different methods A) Abbott IgG II versus DiaSorin Liaison XL, B) Abbott 508 
IgG II versus EDI : C) Abbott IgG II Quantitative (S) versus Abbott IgG Qualitative 509 
(R),. Only Abbott quantitative assay showed linearity (r2=0.9984) and was plotted 510 
against (A) DiaSorin, Quadratic (r2=0.9988), (B) EDI, 4PL (r2=0.9574) and (C) Abbott 511 
Qualitative, 4PL (r2=0.9946).  512 
Figure 5: Dilution of NIBSC working standard 20/162 using the Abbott Diluent. 513 
Dash-dot grey line indicate the identity line. The black dotted line represents the 95% 514 
likelihood asymmetrical CI of the slope 515 
